Co-Authors
This is a "connection" page, showing publications co-authored by EDMUND SCOTT KOPETZ and MICHAEL JAMES OVERMAN.
Connection Strength
2.781
-
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
Score: 0.365
-
Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park). 2008 Nov 30; 22(13):1482-3.
Score: 0.332
-
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 2014 Sep 10; 14:660.
Score: 0.124
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
Score: 0.122
-
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
Score: 0.116
-
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
Score: 0.113
-
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013 Jan 01; 31(1):17-22.
Score: 0.109
-
A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012 May; 19(5):1439-45.
Score: 0.102
-
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011 Oct 01; 17(19):6130-9.
Score: 0.101
-
Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol. 2010 May; 49(4):474-9.
Score: 0.091
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
Score: 0.089
-
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010 Jan 05; 102(1):144-50.
Score: 0.089
-
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
Score: 0.088
-
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
Score: 0.086
-
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603.
Score: 0.084
-
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45.
Score: 0.082
-
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
Score: 0.082
-
Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42.
Score: 0.081
-
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
Score: 0.080
-
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5.
Score: 0.079
-
Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9.
Score: 0.078
-
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
Score: 0.032
-
Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015 Feb 15; 21(4):899-906.
Score: 0.031
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
Score: 0.029
-
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
Score: 0.027
-
A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer. 2012 Apr; 48(6):820-6.
Score: 0.026
-
Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4.
Score: 0.026
-
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer. 2011 Sep; 10(3):178-82.
Score: 0.024
-
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
Score: 0.024
-
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
Score: 0.024
-
Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010 Jun; 210(6):934-41.
Score: 0.023
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.021